NYU Langone Joins $58M NIH Partnership to Accelerate Autoimmune Disease Research

NYU Langone Health has joined the NIH’s Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases program — known as AMP AIM — as a leading center, backed by $58 million in public and private funding. The announcement, made in March 2022, highlights the central role of NYU Langone’s Division of Rheumatology and its partnership with the Judith and Stewart Colton Center for Autoimmunity in driving nationally significant autoimmune research.

AMP AIM is an expansion of the original AMP program, which launched in 2014 with a focus on rheumatoid arthritis and lupus. The expanded program now includes psoriatic disease and Sjögren’s disease, pairing academic researchers with the NIH, the FDA, pharmaceutical companies, and nonprofit partners to identify new therapeutic targets.

NYU Langone is leading three distinct teams within the program. Dr. Jill Buyon is serving as contact principal investigator for LOCKIT, the lupus team focused on kidney disease, cutaneous manifestations, and refractory lupus nephritis, in partnership with Johns Hopkins, Penn, Ohio State, and several other major academic centers. Dr. Jose Scher is leading Micro-TeACH, the program’s microbiome core, and co-leading ELLIPSS, the psoriatic disease team examining the relationship between skin and joint inflammation. Dr. Peter Izmirly is contributing to STAMP, the Sjögren’s disease team, recruiting from NYU Langone’s large outpatient cohort.

Together, the three efforts reflect NYU Langone’s breadth of expertise across autoimmune disease — and the Colton Center’s role as a foundation for that institutional strength.